Breakthrough in Heart Failure therapy: LCZ696 combining ACE-Neprilysin inhibition

Authors

  • Sandeep Lahiry MBBS; Post Graduate Trainee Department of Pharmacology Institute of Post Graduate Medical Education and Research, Kolkata
  • Rajasree Sinha MBBS; Post Graduate Trainee Department of Pediatrics Medical College & Hospital, Kolkata http://orcid.org/0000-0002-8937-0459
  • Shouvik Choudhury MBBS; Post Graduate Trainee Department of Pharmacology Institute of Post Graduate Medical Education and Research, Kolkata http://orcid.org/0000-0003-2913-1955
  • Ayan Mukherjee MBBS; Post Graduate Trainee Department of Pharmacology Institute of Post Graduate Medical Education and Research, Kolkata http://orcid.org/0000-0003-4244-3048

DOI:

https://doi.org/10.3126/ajms.v8i1.15861

Keywords:

LCZ696, Neprilysin, Heart failure

Abstract

Background: Current Heart failure (HF) pharmacotherapy has been unsatisfactory in halting disease progression completely.

Aims and Objective: To evaluate the role of LCZ696, a recent FDA-approved ACE -Neprilysin inhibitor (ARNi) in the management of HF from available trial data.

Materials and Methods: Trial data on ‘LCZ696’ was assessed using PubMed search. Methodological filters were applied to limit retrieval to ‘Randomized Controlled Trial’ (RCT). Bibliographic databases with ‘Human’ data were selected. Trial data comparing ‘LCZ696’ to other drugs or placebo were accessed in full-text. CONSORT guidelines were used for quality assessment. Incomplete methodology, results in abstract form, duplicate publications were excluded. Data extraction forms were piloted and used to obtain uniform quality of data.

Results: Multi-centric trial data (n=2) revealed noticeable benefits with ‘LCZ696’ in patients with HF with reduced ejection fraction (HFrEF), reducing cardiovascular death or hospitalization for HF by 20%; cardiovascular deaths by 20%; hospitalization for HF by 21% ; all cause mortality reduction by 20% as compared to ACE inhibitors (ACEi) (PARADIGM-HF; n=8442). Angioedema was notably absent. Decrease in high sensitivity Troponin-T, improvement in N-terminal-pro-BNP and left atrial dimensions suggested reduction of myocardial injury in HF with preserved ejection fraction (HFpEF) (PARAMOUNT trial; n=301).

Conclusion: There is convincing evidence of the role of novel ARNi (Angiotensin receptor – Neprilysin Inhibitors) in HF pharmacotherapy. Its role in other cardiovascular conditions merits assessment.

Asian Journal of Medical Sciences Vol.8(1) 2017 1-4

Downloads

Download data is not yet available.
Abstract
997
PDF
1146

Downloads

Published

2017-01-03

How to Cite

Lahiry, S., Sinha, R., Choudhury, S., & Mukherjee, A. (2017). Breakthrough in Heart Failure therapy: LCZ696 combining ACE-Neprilysin inhibition. Asian Journal of Medical Sciences, 8(1), 1–4. https://doi.org/10.3126/ajms.v8i1.15861

Issue

Vol. 8 No. 1 (2017)

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

  1. The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).